Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
TV & Film
Sports
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/f1/b9/ab/f1b9abe2-cfe0-a121-a86e-a9e051e550b8/mza_3957851291692824620.png/600x600bb.jpg
The Fellow on Call: The Heme/Onc Podcast
Rouleaux University Medical Center
147 episodes
1 week ago
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
Show more...
Medicine
Education,
How To,
Health & Fitness,
Science,
Life Sciences
RSS
All content for The Fellow on Call: The Heme/Onc Podcast is the property of Rouleaux University Medical Center and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
Show more...
Medicine
Education,
How To,
Health & Fitness,
Science,
Life Sciences
https://images.squarespace-cdn.com/content/v1/61b273ac9be6aa2250498c9e/1733858456914-L2U0E35ARHL7W9HEGOXL/AML+pt10.jpg?format=1500w
Episode 124: AML Series, Pt 10 - Allogeneic transplant for AML
The Fellow on Call: The Heme/Onc Podcast
11 months ago
Episode 124: AML Series, Pt 10 - Allogeneic transplant for AML
In today’s episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transplant for the treatment of AML. Episode contents: - What are the different conditioning regimens available? - How do we decide which regimen is optimal for our patients? - What is the role of MRD testing? - What is the role of maintenance therapy post-transplant? - What are treatment options for GVHD? - A discussion on racial disparities in transplant ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
The Fellow on Call: The Heme/Onc Podcast
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast